MedPath

Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac

Not Applicable
Recruiting
Conditions
Rectal Cancer
Head and Neck Cancer
Liver Cancer
Breast Cancer
Esophageal Cancer
Prostate Cancer
Oligometastasis
Registration Number
NCT04172753
Lead Sponsor
University Hospital Tuebingen
Brief Summary

This study investigates the feasibility of imaging and treatment on a novel 1.5 T MR-Linac radiotherapy hybrid device.

Detailed Description

Novel hybrid devices combine magnetic resonance imaging (MRI) and a linear accelerator in a single device. The superior soft tissue contrast compared with cone-beam computed tomography based treatment and the possibility for daily plan adaptation promise a higher precision of treatment, better target volume coverage and normal tissue sparing. In a first step the present study will test the feasibility of imaging and treatment on the 1.5 T MR-Linac.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
472
Inclusion Criteria
  • existing indication for radiation therapy
  • minimum age 18 years, no upper age limit
  • capacity for consent
  • Informed consent
Exclusion Criteria
  • contraindication for MRI (claustrophobia, metallic implants not applicable for MRI
  • pregnancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Feasibility of online MR guided RadiotherapyDuring every single patients treatment (i.e. between one to seven weeks after the first application of radiotherapy)

Treatment of a patient is considered feasible when 85% of treatments were completed as planned in this patient

Secondary Outcome Measures
NameTimeMethod
Time analysisDuring every single patients treatment (i.e. between one to seven weeks after the first application of radiotherapy)

Time required for online MR guided radiotherapy

Trial Locations

Locations (1)

University Hospital Tübingen, Department of Radiation Oncology

🇩🇪

Tübingen, Baden-Württemberg, Germany

University Hospital Tübingen, Department of Radiation Oncology
🇩🇪Tübingen, Baden-Württemberg, Germany

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.